

Ken-ichi Kusakabe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1943276/publications.pdf>

Version: 2024-02-01

21
papers

597
citations

687363

13
h-index

752698

20
g-index

22
all docs

22
docs citations

22
times ranked

633
citing authors

#	ARTICLE	IF	CITATIONS
1	A Switch of Enantiofacial Selectivities Using Designed Similar Chiral Ligands in Zirconium-Catalyzed Asymmetric Aza Diels-Alder Reactions. <i>Journal of Organic Chemistry</i> , 1999, 64, 4220-4221.	3.2	112
2	Chiral Catalyst Optimization Using Both Solid-Phase and Liquid-Phase Methods in Asymmetric Aza Diels-Alder Reactions. <i>Organic Letters</i> , 2000, 2, 1225-1227.	4.6	94
3	Discovery of Imidazo[1,2- <i>b</i>]pyridazine Derivatives: Selective and Orally Available Mps1 (TTK) Kinase Inhibitors Exhibiting Remarkable Antiproliferative Activity. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 1760-1775.	6.4	61
4	Indazole-Based Potent and Cell-Active Mps1 Kinase Inhibitors: Rational Design from Pan-Kinase Inhibitor Anthrapyrazolone (SP600125). <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4343-4356.	6.4	39
5	Design, synthesis, and binding mode prediction of 2-pyridone-based selective CB2 receptor agonists. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 2045-2055.	3.0	32
6	Diaminopyridine-Based Potent and Selective Mps1 Kinase Inhibitors Binding to an Unusual Flipped-Peptide Conformation. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 560-564.	2.8	31
7	Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based β -Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 1873-1888.	6.4	30
8	Rational Design of Novel 1,3-Oxazine Based β -Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust β Reduction in the Brain. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5122-5137.	6.4	29
9	Structure-Based Design of Selective β -Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: Targeting the Flap to Gain Selectivity over BACE2. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 5080-5095.	6.4	29
10	Discovery of Potent and Centrally Active 6-Substituted 5-Fluoro-1,3-dihydro-oxazine β -Secretase (BACE1) Inhibitors via Active Conformation Stabilization. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5525-5546.	6.4	28
11	Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020). <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 25-52.	5.0	22
12	Selective CB2 agonists with anti-pruritic activity: Discovery of potent and orally available bicyclic 2-pyridones. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 3154-3163.	3.0	16
13	A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 2247-2260.	3.0	15
14	Synthesis of a 6-CF ₃ -Substituted 2-Amino-dihydro-1,3-thiazine β -Secretase Inhibitor by <i>N,N</i> -Diethylaminosulfur Trifluoride-Mediated Chemoselective Cyclization. <i>Journal of Organic Chemistry</i> , 2019, 84, 4893-4897.	3.2	11
15	Structure-Based Approaches to Improving Selectivity through Utilizing Explicit Water Molecules: Discovery of Selective β -Secretase (BACE1) Inhibitors over BACE2. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3075-3085.	6.4	11
16	JNJ-67569762, A 2-Aminotetrahydropyridine-Based Selective BACE1 Inhibitor Targeting the S3 Pocket: From Discovery to Clinical Candidate. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14175-14191.	6.4	10
17	Trifluoromethyl Dihydrothiazine-Based β -Secretase (BACE1) Inhibitors with Robust Central β -Amyloid Reduction and Minimal Covalent Binding Burden. <i>ChemMedChem</i> , 2019, 14, 1894-1910.	3.2	8
18	Discovery of an Extremely Potent Thiazine-Based β -Secretase Inhibitor with Reduced Cardiovascular and Liver Toxicity at a Low Projected Human Dose. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9331-9337.	6.4	7

#	ARTICLE	IF	CITATIONS
19	Balancing potency and basicity by incorporating fluoropyridine moieties: Discovery of a 1-amino-3,4-dihydro-2,6-naphthyridine BACE1 inhibitor that affords robust and sustained central A β reduction. <i>European Journal of Medicinal Chemistry</i> , 2021, 216, 113270.	5.5	7
20	Discovery of Extremely Selective Fused Pyridine-Derived β -Site Amyloid Precursor Protein-Cleaving Enzyme (BACE1) Inhibitors with High In Vivo Efficacy through 10s Loop Interactions. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14165-14174.	6.4	4
21	Facile Construction of an Amino-1,3-Oxazine Scaffold using Burgess Reagent Under Mild Conditions. <i>Tetrahedron Letters</i> , 2021, 64, 152684.	1.4	1